ITMI20011986A0 - Metodo e composizione per l'attivazione di cellule presentanti l'antigene - Google Patents

Metodo e composizione per l'attivazione di cellule presentanti l'antigene

Info

Publication number
ITMI20011986A0
ITMI20011986A0 IT2001MI001986A ITMI20011986A ITMI20011986A0 IT MI20011986 A0 ITMI20011986 A0 IT MI20011986A0 IT 2001MI001986 A IT2001MI001986 A IT 2001MI001986A IT MI20011986 A ITMI20011986 A IT MI20011986A IT MI20011986 A0 ITMI20011986 A0 IT MI20011986A0
Authority
IT
Italy
Prior art keywords
activation
composition
presenting cells
antigen presenting
antigen
Prior art date
Application number
IT2001MI001986A
Other languages
English (en)
Inventor
Marco Bianchi
Angelo Manfredi
Original Assignee
San Raffaele Centro Fond
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by San Raffaele Centro Fond filed Critical San Raffaele Centro Fond
Priority to IT2001MI001986A priority Critical patent/ITMI20011986A1/it
Publication of ITMI20011986A0 publication Critical patent/ITMI20011986A0/it
Priority to DE60233147T priority patent/DE60233147D1/de
Priority to US10/489,878 priority patent/US20040242481A1/en
Priority to AT02775057T priority patent/ATE437652T1/de
Priority to JP2003530326A priority patent/JP2005508913A/ja
Priority to CA002461091A priority patent/CA2461091A1/en
Priority to PCT/IB2002/004080 priority patent/WO2003026691A2/en
Priority to EP02775057A priority patent/EP1432441B1/en
Priority to AU2002341266A priority patent/AU2002341266B2/en
Publication of ITMI20011986A1 publication Critical patent/ITMI20011986A1/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IT2001MI001986A 2001-09-25 2001-09-25 Metodo e composizione per l'attivazione di cellule presentanti l'antigene ITMI20011986A1 (it)

Priority Applications (9)

Application Number Priority Date Filing Date Title
IT2001MI001986A ITMI20011986A1 (it) 2001-09-25 2001-09-25 Metodo e composizione per l'attivazione di cellule presentanti l'antigene
DE60233147T DE60233147D1 (de) 2001-09-25 2002-09-25 Verwendung von hmgb1 zur aktivierung dendritischer zellen
US10/489,878 US20040242481A1 (en) 2001-09-25 2002-09-25 Use of hmgb1 for the activation of dendritic cells
AT02775057T ATE437652T1 (de) 2001-09-25 2002-09-25 Verwendung von hmgb1 zur aktivierung dendritischer zellen
JP2003530326A JP2005508913A (ja) 2001-09-25 2002-09-25 樹状細胞の活性化のためのｈｍｇｂ１の使用
CA002461091A CA2461091A1 (en) 2001-09-25 2002-09-25 Use of hmgb1 for the activation of dendritic cells
PCT/IB2002/004080 WO2003026691A2 (en) 2001-09-25 2002-09-25 Use of hmgb1 for the activation of dendritic cells
EP02775057A EP1432441B1 (en) 2001-09-25 2002-09-25 Use of hmgb1 for the activation of dendritic cells
AU2002341266A AU2002341266B2 (en) 2001-09-25 2002-09-25 Use of HMGB1 for the activation of dendritic cells

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT2001MI001986A ITMI20011986A1 (it) 2001-09-25 2001-09-25 Metodo e composizione per l'attivazione di cellule presentanti l'antigene

Publications (2)

Publication Number Publication Date
ITMI20011986A0 true ITMI20011986A0 (it) 2001-09-25
ITMI20011986A1 ITMI20011986A1 (it) 2003-03-25

Family

ID=11448420

Family Applications (1)

Application Number Title Priority Date Filing Date
IT2001MI001986A ITMI20011986A1 (it) 2001-09-25 2001-09-25 Metodo e composizione per l'attivazione di cellule presentanti l'antigene

Country Status (9)

Country Link
US (1) US20040242481A1 (it)
EP (1) EP1432441B1 (it)
JP (1) JP2005508913A (it)
AT (1) ATE437652T1 (it)
AU (1) AU2002341266B2 (it)
CA (1) CA2461091A1 (it)
DE (1) DE60233147D1 (it)
IT (1) ITMI20011986A1 (it)
WO (1) WO2003026691A2 (it)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050112121A1 (en) * 1992-04-30 2005-05-26 Yale University Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids
GB0226251D0 (en) * 2002-11-11 2002-12-18 San Raffaele Centro Fond Acetylated protein
EP1899376A2 (en) 2005-06-16 2008-03-19 The Feinstein Institute for Medical Research Antibodies against hmgb1 and fragments thereof
US7829097B2 (en) 2006-02-06 2010-11-09 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Use of HMGB1 for protection against ischemia reperfusion injury
US20090202500A1 (en) * 2006-10-30 2009-08-13 Genomix Co., Ltd. Pharmaceuticals That Promote Functional Regeneration of Damaged Tissues
US20100173277A1 (en) * 2007-02-15 2010-07-08 Fukuoka University Agent for Suppressing Rejection in Organ Transplantation Comprising Anti-HMGB-1 Antibody
TW200902063A (en) 2007-02-15 2009-01-16 Univ Kumamoto Therapeutic agent comprising antibody capable of specifically binding to human hmgb-1 as active ingredient
JP5241518B2 (ja) 2007-02-15 2013-07-17 国立大学法人九州大学 抗ｈｍｇｂ−１抗体を含む間質性肺疾患治療剤
CA3156538C (en) 2007-11-01 2023-12-12 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses to eimeria
RU2571230C2 (ru) 2008-04-30 2015-12-20 Дженомикс Ко., Лтд. Способ сбора функциональных клеток in vivo с высокой эффективностью
JP5660889B2 (ja) 2008-04-30 2015-01-28 株式会社ジェノミックス 末梢循環への骨髄由来多能性幹細胞動員薬
BRPI0911436A2 (pt) * 2008-04-30 2016-07-12 Genomix Co Ltd vetores contendo o dna codificando as proteínas s100a8 e s100a9 e sua utilização para confecção de composições farmacêuticas para promoção da regeneração funcional de tecido lesionado
RU2599448C2 (ru) 2009-10-28 2016-10-10 Дженомикс Ко., Лтд. Средства для стимуляции регенерации тканей путем привлечения мезенхимных стволовых клеток и/или плюрипотентных стволовых клеток костного мозга в кровь
ES2643646T3 (es) 2010-01-21 2017-11-23 The Board Of Trustees Of The University Of Arkansas Vectores de vacuna y métodos para potenciar las respuestas inmunitarias
AU2011235296C1 (en) 2010-03-29 2017-05-04 Nationwide Children's Hospital, Inc. Compositions and methods for the removal of biofilms
EP2579901B1 (en) * 2010-06-09 2019-08-07 The Board of Trustees of The University of Arkansas Vaccine and methods to reduce campylobacter infection
EP2613797B1 (en) * 2010-09-09 2015-11-04 University Of Southern California Compositions and methods for the removal of biofilms
EP2703487B1 (en) 2011-04-26 2018-06-27 Genomix Co., Ltd. Peptide for inducing regeneration of tissue and use thereof
WO2012170742A2 (en) * 2011-06-07 2012-12-13 University Of Hawaii Treatment and prevention of cancer with hmgb1 antagonists
US9244074B2 (en) 2011-06-07 2016-01-26 University Of Hawaii Biomarker of asbestos exposure and mesothelioma
MX361259B (es) 2012-10-25 2018-11-30 Univ Osaka Uso de un fragmento de peptido hmgb1 para el tratamiento del infarto al miocardio.
SG11201503215XA (en) 2012-10-25 2015-06-29 Genomix Co Ltd Novel method for treating spinal cord injury using hmgb1 fragment
NZ711019A (en) 2013-02-14 2019-07-26 Univ Arkansas Compositions and methods of enhancing immune responses to eimeria or limiting eimeria infection
BR112015023024B1 (pt) 2013-03-15 2022-04-19 The Board Of Trustees Of The University Of Arkansas Vetor de vacina e composições farmacêuticas compreendendo o mesmo
US11274144B2 (en) 2013-06-13 2022-03-15 Research Institute At Nationwide Children's Hospital Compositions and methods for the removal of biofilms
US9745366B2 (en) 2013-09-23 2017-08-29 University Of Southern California Compositions and methods for the prevention of microbial infections
US10233234B2 (en) 2014-01-13 2019-03-19 Trellis Bioscience, Llc Binding moieties for biofilm remediation
US11248040B2 (en) 2013-09-26 2022-02-15 Trellis Bioscience, Llc Binding moieties for biofilm remediation
AU2016303688B2 (en) 2015-07-31 2023-06-15 Research Institute At Nationwide Children's Hospital Peptides and antibodies for the removal of biofilms
GB201600075D0 (en) 2016-01-03 2016-02-17 Glaxosmithkline Biolog Sa Immunogenci composition
WO2017192671A1 (en) 2016-05-03 2017-11-09 The Board Of Trustees Of The University Of Arkansas Yeast vaccine vector including immunostimulatory and antigenic polypeptides and methods of using the same
WO2018047917A1 (ja) * 2016-09-09 2018-03-15 国立大学法人 東京大学 Ｈｍｇタンパク質と抗ｃｄ４抗体又は免疫チェックポイント制御剤との組み合わせによる相乗的抗腫瘍効果
MX2019008949A (es) 2017-01-27 2019-10-07 Stemrim Inc Agente terapeutico para cardiomiopatia, infarto al miocardio antiguo e insuficiencia cardiaca cronica.
CA3056088A1 (en) 2017-03-15 2018-09-20 Research Institute At Nationwide Children's Hospital Composition and methods for disruption of bacterial biofilms without accompanying inflammation
JPWO2019107530A1 (ja) 2017-12-01 2020-11-26 株式会社ステムリム 炎症性腸疾患の治療薬

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5214131A (en) * 1988-05-06 1993-05-25 Sumitomo Pharmaceuticals Company, Limited Polyethylene glycol derivatives, modified peptides and production thereof
US5091176A (en) * 1988-11-02 1992-02-25 W. R. Grace & Co.-Conn. Polymer-modified peptide drugs having enhanced biological and pharmacological activities
JPH04218000A (ja) * 1990-02-13 1992-08-07 Kirin Amgen Inc 修飾ポリペプチド
US5811512A (en) * 1991-08-22 1998-09-22 The Trustees Of The University Of Pennsylvania Non-peptide peptidomimetics and related cyclic hexapeptides
US5580853A (en) * 1994-03-22 1996-12-03 New England Deaconess Hospital Modified polypeptides with increased biological activity
US5891418A (en) * 1995-06-07 1999-04-06 Rhomed Incorporated Peptide-metal ion pharmaceutical constructs and applications
FR2739292B1 (fr) * 1995-09-28 1997-10-31 Rhone Poulenc Rorer Sa Composition pharmaceutique utile pour la transfection d'acides nucleiques et ses utilisations
IT1299583B1 (it) * 1998-05-19 2000-03-16 Vander Way Limited Uso di proteine hmg-i per la preparazione di medicamenti ad attivita' citotossica
US6100090A (en) * 1999-06-25 2000-08-08 Isis Pharmaceuticals Inc. Antisense inhibition of PI3K p85 expression
US6303321B1 (en) * 1999-02-11 2001-10-16 North Shore-Long Island Jewish Research Institute Methods for diagnosing sepsis

Also Published As

Publication number Publication date
WO2003026691A2 (en) 2003-04-03
EP1432441B1 (en) 2009-07-29
DE60233147D1 (de) 2009-09-10
ITMI20011986A1 (it) 2003-03-25
EP1432441A2 (en) 2004-06-30
CA2461091A1 (en) 2003-04-03
JP2005508913A (ja) 2005-04-07
WO2003026691A3 (en) 2003-05-30
ATE437652T1 (de) 2009-08-15
AU2002341266B2 (en) 2007-11-15
US20040242481A1 (en) 2004-12-02

Similar Documents

Publication Publication Date Title
ITMI20011986A0 (it) Metodo e composizione per l'attivazione di cellule presentanti l'antigene
HUP0600688A2 (en) Methods of administering anti-tnf alpha antibodies
ZA200305825B (en) Modified antibodies and methods of use
EP1551875A4 (en) TAMPON PREPARATIONS FOR CONCENTRATING ANTIBODIES AND METHODS FOR USE THEREOF
LT3718564T (lt) Nauji anti-il-13 antikūnai ir jų panaudojimas
PT1438068E (pt) Anticorpos inibidores de gdf-8 e utilizações dos mesmos
IL149701A0 (en) Use of anti-ctla-4 antibodies
AU2002340167A8 (en) Anti-hla-dr antibodies and the methods of using thereof
ATE420659T1 (de) Criptoblockierende antikörper und deren verwendung
DE60223761D1 (de) Polierzusammensetzung und Polierverfahren unter deren Verwendung
AU2002365228A1 (en) Antigen panels and methods of using the same
AU2002368056A1 (en) Novel pla2 enzyme, it's antibody, enzyme inhibitor and use and the preparation methods thereof
AU2002316162A1 (en) Method of increasing anti-neugc antibody levels in blood
AU2002365269A8 (en) Mut-il-18 or mut-il-18r proteins, antibodies, compositions, methods and uses
AU2003276844A8 (en) Formulations of modified antibodies and methods of making the same
AU2002365894A8 (en) Antibodies to magmas and uses thereof
GB0119497D0 (en) Expression of modified antibodies in avian cells
IT1315150B1 (it) Dispositivo e metodo per l'assemblaggio di telai smontabili di mobili
EP1501870A4 (en) RSV PROTEINS, ANTIBODIES, COMPOSITIONS, PROCESSES AND USES
ITMI20020052A0 (it) Procedimento per l'idrolisi selettiva di nucleosidi poliesteri
ITBO20010160A0 (it) Dispositivo d'inserimento di guarnizioni in sedi odi elementi allungati
ITBO20030419A1 (it) Metodo per la costruzione e l'assemblaggio di articoli per bigiotteria ed oreficeria.
ITUD20020075A1 (it) Metodo per la fabbricazione di occhiali componibili e modulari ed occhiali cosi' ottenuti
IT1321195B1 (it) Metodo per la realizzazione di lavabi ed altri manufatti in vetrocristallo e simili.
AU2003212142A1 (en) Downregulation of ca 125 tumor antigen and uses thereof